Legend Biotech Corp (NASDAQ:LEGN) disclosed that its Chief Executive Officer, Ingrid Zhang, acquired ordinary shares in the company on November 17, 2026. The total value of the purchase was $163,200.
Ms. Zhang bought 20,000 ordinary shares at a price of $8.16 per ordinary share. That per-share price reflects a converted purchase price of $16.32 per American Depositary Share (ADS), with each ADS representing two ordinary shares of the Issuer. The timing of the insider purchase is notable because the stock is currently trading at $15.25, close to its 52-week low of $15.14, after declining nearly 46% over the past year.
Following the acquisition, Ms. Zhang directly holds 1,151,860 ordinary shares of Legend Biotech Corp. According to InvestingPro analysis, the stock appears undervalued at current levels, and the company is featured on the platform's Most Undervalued list. Investors seeking deeper insights can access Legend Biotech's comprehensive Pro Research Report, available for this and 1,400+ other US equities.
In other recent news, Legend Biotech reported its third-quarter 2026 financial results, which included revenue of $359.5 million, slightly surpassing Wall Street's expectations of $358.63 million. However, the company's earnings per share were a loss of $0.13, significantly missing the forecasted loss of $0.0037. Despite the earnings miss, Legend Biotech highlighted a 36% year-over-year increase in CARVYKTI net trade sales, totaling $710 million for the quarter. The company also improved its fourth-quarter product gross-margin outlook to the high-50% range. H.C. Wainwright reiterated a Buy rating for Legend Biotech, maintaining a price target of $65.00. The firm noted Legend's progress in reaching half of the U.S. Carvykti apheresis for second- and third-line patients. These developments indicate a mixed financial performance but highlight potential growth areas for the company.
Legend Biotech's stock closed at $15.25, down $0.85 or 5.28%, on the day of the disclosure. In after-hours trading, the stock rose $0.20 or 1.30% to $15.45.
Investors seeking to determine whether LEGN is a bargain can use InvestingPro's Fair Value estimate, which runs 17 proven valuation models on the stock and provides a single number along with the potential upside or downside against the current price. The same tool can be applied to thousands of other stocks, helping investors avoid guessing which ones are already priced for perfection. More than 370,000 investors rely on InvestingPro tools from Investing.com to validate their trading ideas. Full access is currently available at 55% off for Black Friday early birds.